{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:36:20Z","timestamp":1791765380483,"version":"4.3.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jvascsurg.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Vascular Surgery"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jvs.2024.01.010","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T03:11:06Z","timestamp":1704942666000},"page":"279-287","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["The effect of cilostazol on late outcomes after endovascular treatment for occlusive femoropopliteal disease"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6077-007X","authenticated-orcid":false,"given":"George","family":"Galyfos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Chamzin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3592-7132","authenticated-orcid":false,"given":"Konstantinos","family":"Saliaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Theodorou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyriaki","family":"Konstantinou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frangiska","family":"Sigala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6309-5201","authenticated-orcid":false,"given":"Konstantinos","family":"Filis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvs.2024.01.010_bib1","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","volume":"39","author":"Aboyans","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jvs.2024.01.010_bib2","first-page":"2682","article-title":"Chronic limb-threatening ischemia and the need for revascularization","volume":"12","author":"Berchiolli","year":"2023","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jvs.2024.01.010_bib3","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1080\/14779072.2019.1675512","article-title":"Newly approved devices for endovascular treatment of femoropopliteal disease: a review of clinical evidence","volume":"17","author":"Giannopoulos","year":"2019","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.jvs.2024.01.010_bib4","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1055\/s-0034-1393971","article-title":"Treating femoropopliteal disease: established and emerging technologies","volume":"31","author":"Diamantopoulos","year":"2014","journal-title":"Semin Intervent Radiol"},{"key":"10.1016\/j.jvs.2024.01.010_bib5","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jvs.2009.01.035","article-title":"National trends in lower extremity bypass surgery, endovascular interventions, and major amputations","volume":"50","author":"Goodney","year":"2009","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvs.2024.01.010_bib6","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1053\/j.semvascsurg.2022.04.010","article-title":"Endovascular treatment of femoropopliteal arterial occlusive disease: current techniques and limitations","volume":"35","author":"Aru","year":"2022","journal-title":"Semin Vasc Surg"},{"key":"10.1016\/j.jvs.2024.01.010_bib7","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s10557-021-07187-x","article-title":"Cilostazol: a review of basic mechanisms and clinical uses","volume":"36","author":"Kherallah","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jvs.2024.01.010_bib8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5758\/vsi.2017.33.3.89","article-title":"Cilostazol for secondary prevention of stroke: should the guidelines perhaps be extended?","volume":"33","author":"Galyfos","year":"2017","journal-title":"Vasc Specialist Int"},{"key":"10.1016\/j.jvs.2024.01.010_bib9","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1024\/0301-1526\/a000649","article-title":"Conservative treatment of patients with thromboangiitis obliterans or cannabis-associated arteritis presenting with critical lower limb ischaemia","volume":"46","author":"Galyfos","year":"2017","journal-title":"Vasa"},{"key":"10.1016\/j.jvs.2024.01.010_bib10","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s40265-015-0364-3","article-title":"Clinical efficacy and safety of cilostazol: a critical review of the literature","volume":"75","author":"Rogers","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.jvs.2024.01.010_bib11","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2174\/157489009787260025","article-title":"A\u00a0review of cilostazol, a phosphodiesterase inhibitor, and its role in preventing both coronary and peripheral arterial restenosis following endovascular therapy","volume":"4","author":"Dindyal","year":"2009","journal-title":"Recent Pat Cardiovasc Drug Discov"},{"key":"10.1016\/j.jvs.2024.01.010_bib12","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1177\/1526602815619409","article-title":"Meta-analysis of studies evaluating the effect of cilostazol on major outcomes after carotid stenting","volume":"23","author":"Galyfos","year":"2016","journal-title":"J\u00a0Endovasc Ther"},{"key":"10.1016\/j.jvs.2024.01.010_bib13","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/j.jvs.2013.11.096","article-title":"Cilostazol is associated with improved outcomes after peripheral endovascular interventions","volume":"59","author":"Warner","year":"2014","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvs.2024.01.010_bib15","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.jvs.2024.01.010_bib16","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1253\/circj.69.1256","article-title":"Cilostazol reduces target lesion revascularization after percutaneous transluminal angioplasty in the femoropopliteal artery","volume":"69","author":"Iida","year":"2005","journal-title":"Circ J"},{"key":"10.1016\/j.jvs.2024.01.010_bib17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.clinthera.2010.01.007","article-title":"Effects of oral cilostazol 100 mg BID on long-term patency after percutaneous transluminal angioplasty in patients with femoropopliteal disease undergoing hemodialysis: a retrospective chart review in Japanese patients","volume":"32","author":"Ishii","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.jvs.2024.01.010_bib18","first-page":"83","article-title":"A\u00a0better effect of cilostazol for reducing in-stent restenosis after femoropopliteal artery stent placement in comparison with ticlopidine","volume":"4","author":"Ikushima","year":"2011","journal-title":"Med Devices (Auckl)"},{"key":"10.1016\/j.jvs.2024.01.010_bib19","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1177\/0003319714551361","article-title":"Effect of cilostazol following endovascular intervention for peripheral artery disease","volume":"66","author":"Nanto","year":"2015","journal-title":"Angiology"},{"key":"10.1016\/j.jvs.2024.01.010_bib20","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1177\/1526602817719284","article-title":"Impact of cilostazol administration on femoropopliteal in-stent restenosis","volume":"24","author":"Tomoi","year":"2017","journal-title":"J\u00a0Endovasc Ther"},{"key":"10.1016\/j.jvs.2024.01.010_bib21","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jvs.2016.10.098","article-title":"ZEPHYR Investigators. Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease","volume":"65","author":"Zen","year":"2017","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvs.2024.01.010_bib22","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1177\/1526602818771358","article-title":"STOP-IC investigators. Sustained effectiveness of cilostazol after endovascular treatment of femoropopliteal lesions: Midterm follow-up from the sufficient treatment of peripheral intervention by cilostazol (STOP-IC) study","volume":"25","author":"Soga","year":"2018","journal-title":"J\u00a0Endovasc Ther"},{"key":"10.1016\/j.jvs.2024.01.010_bib23","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.118.006564","article-title":"DEBATE in SFA investigators. Drug-eluting versus bare-metal stent implantation with or without cilostazol in the treatment of the superficial femoral artery","volume":"11","author":"Miura","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jvs.2024.01.010_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/heartasia-2018-011114","article-title":"Antithrombotic therapy after femoropopliteal artery stenting: 12-month results from Japan Postmarketing Surveillance","volume":"11","author":"Kawarada","year":"2019","journal-title":"Heart Asia"},{"key":"10.1016\/j.jvs.2024.01.010_bib25","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.5551\/jat.63874","article-title":"Clinical impact of additional cilostazol treatment on restenosis risk following heparin-bonded stent graft implantation: sub-analysis from the viabahn stent-graft placement for femoropopliteal diseases requiring endovascular therapy (VANQUISH) study","volume":"30","author":"Tobita","year":"2023","journal-title":"J\u00a0Atheroscler Thromb"},{"key":"10.1016\/j.jvs.2024.01.010_bib26","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1253\/circj.CJ-08-0289","article-title":"Evaluation of the antiplatelet effects of cilostazol, a phosphodiesterase 3 inhibitor, by VASP phosphorylation and platelet aggregation","volume":"72","author":"Yamamoto","year":"2008","journal-title":"Circ J"},{"key":"10.1016\/j.jvs.2024.01.010_bib27","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1161\/ATVBAHA.111.230987","article-title":"Cilostazol promotes vascular smooth muscles cell differentiation through the cAMP response element-binding protein-dependent pathway","volume":"31","author":"Chen","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jvs.2024.01.010_bib28","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1161\/01.HYP.35.1.237","article-title":"Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21","volume":"35","author":"Hayashi","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.jvs.2024.01.010_bib29","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1007\/s001250100593","article-title":"Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model","volume":"44","author":"Aoki","year":"2001","journal-title":"Diabetologia"},{"key":"10.1016\/j.jvs.2024.01.010_bib30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0021-9150(98)00147-6","article-title":"Effects of a single local administration of cilostazol on neointimal formation in balloon-injured rat carotid artery","volume":"142","author":"Ishizaka","year":"1999","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jvs.2024.01.010_bib31","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.hjc.2018.04.006","article-title":"Critical evaluation on proper antithrombotic treatment in different groups of patients undergoing vascular surgery","volume":"59","author":"Filis","year":"2018","journal-title":"Hellenic J Cardiol"},{"key":"10.1016\/j.jvs.2024.01.010_bib32","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1161\/CIR.0b013e31828b82aa","article-title":"Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF\/AHA guideline recommendations): a report of the American college of cardiology foundation\/American heart association task force on practice guidelines","volume":"127","author":"Anderson","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jvs.2024.01.010_bib33","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ijcard.2013.12.295","article-title":"Cilostazol enhances mobilization and proliferation of endothelial progenitor cells and collateral formation by modifying vasculo-angiogenic biomarkers in peripheral arterial disease","volume":"172","author":"Chao","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jvs.2024.01.010_bib34","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1161\/STROKEAHA.110.609834","article-title":"Cilostazol, not aspirin, reduces ischemic brain injury via endothelial protection in spontaneously hypertensive rats","volume":"42","author":"Oyama","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.jvs.2024.01.010_bib35","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jvs.2014.11.067","article-title":"Cilostazol and freedom from amputation after lower extremity revascularization","volume":"61","author":"Neel","year":"2015","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvs.2024.01.010_bib36","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1177\/1358863X19838327","article-title":"Outcomes with cilostazol after endovascular therapy of peripheral artery disease","volume":"24","author":"Megaly","year":"2019","journal-title":"Vasc Med"},{"key":"10.1016\/j.jvs.2024.01.010_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2014-000154","article-title":"Cilostazol increases patency and reduces adverse outcomes in percutaneous femoropopliteal revascularisation: a meta-analysis of randomised controlled trials","volume":"1","author":"Benjo","year":"2014","journal-title":"Open Heart"},{"key":"10.1016\/j.jvs.2024.01.010_bib38","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jvs.2020.08.125","article-title":"Literature review and meta-analysis of the efficacy of cilostazol on limb salvage rates after infrainguinal endovascular and open revascularization","volume":"73","author":"Desai","year":"2021","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvs.2024.01.010_bib39","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jvs.2008.02.062","article-title":"Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions","volume":"48","author":"Iida","year":"2008","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvs.2024.01.010_bib40","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1161\/CIRCULATIONAHA.112.000711","article-title":"Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study","volume":"127","author":"Iida","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jvs.2024.01.010_bib41","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jacc.2008.09.020","article-title":"Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication","volume":"53","author":"Soga","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jvs.2024.01.010_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0270992","article-title":"Cilostazol effectiveness in reducing drug-coated stent restenosis in the superficial femoral artery: the ZERO study","volume":"17","author":"Miura","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.jvs.2024.01.010_bib43","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s13300-020-00860-8","article-title":"Long-term cilostazol treatment and predictive factors on outcomes of endovascular intervention in patients with diabetes mellitus and critical limb ischemia","volume":"11","author":"Lee","year":"2020","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jvs.2024.01.010_bib44","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/S0002-9149(02)02869-2","article-title":"Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication","volume":"90","author":"Thompson","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jvs.2024.01.010_bib45","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jvs.2007.10.009","article-title":"Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: a Study in Long-term Effects)","volume":"47","author":"Hiatt","year":"2008","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvs.2024.01.010_bib46","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2014-000068","article-title":"Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials","volume":"1","author":"Bangalore","year":"2014","journal-title":"Open Heart"},{"key":"10.1016\/j.jvs.2024.01.010_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063499","article-title":"Practice-based evidence: profiling the safety of cilostazol by text-mining of clinical notes","volume":"8","author":"Leeper","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jvs.2024.01.010_bib48","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jacc.2010.08.631","volume":"57","author":"Suh","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jvs.2024.01.010_bib49","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.amjcard.2013.06.010","article-title":"Differential impact of cilostazol on restenosis according to implanted stent type (from a pooled analysis of three DECLARE randomized trials)","volume":"112","author":"Lee","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jvs.2024.01.010_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108514","article-title":"Cilostazol is an effective causal therapy for preventing paclitaxel-induced peripheral neuropathy by suppression of Schwann cell dedifferentiation","volume":"188","author":"Koyanagi","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jvs.2024.01.010_bib51","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.atherosclerosis.2013.03.008","article-title":"Cilostazol protects vessels against hyperglycemic injury and accelerates healing after implantation of drug-eluting stent in a type 1 diabetes mellitus rat aorta stent model","volume":"228","author":"Kwon","year":"2013","journal-title":"Atherosclerosis"}],"container-title":["Journal of Vascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0741521424000685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0741521424000685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T02:45:31Z","timestamp":1782960331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0741521424000685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0741521424000685"],"URL":"https:\/\/doi.org\/10.1016\/j.jvs.2024.01.010","relation":{},"ISSN":["0741-5214"],"issn-type":[{"value":"0741-5214","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of cilostazol on late outcomes after endovascular treatment for occlusive femoropopliteal disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Vascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvs.2024.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the Society for Vascular Surgery. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}